APA citiranje

Enjoji, M., Machida, K., Kohjima, M., Kato, M., Kotoh, K., Matsunaga, K., . . . Nakamuta, M. (2010). NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. BioMed Central.

Citação norma Chicago

Enjoji, Munechika, Kazuyuki Machida, Motoyuki Kohjima, Masaki Kato, Kazuhiro Kotoh, Kazuhisa Matsunaga, Manabu Nakashima, and Makoto Nakamuta. NPC1L1 Inhibitor Ezetimibe Is a Reliable Therapeutic Agent for Non-obese Patients With Nonalcoholic Fatty Liver Disease. BioMed Central, 2010.

MLA citiranje

Enjoji, Munechika, et al. NPC1L1 Inhibitor Ezetimibe Is a Reliable Therapeutic Agent for Non-obese Patients With Nonalcoholic Fatty Liver Disease. BioMed Central, 2010.